An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Dovitinib (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Apr 2016 Results published in the Hepatology
    • 13 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2014 Planned End Date changed from 1 Jul 2013 to 1 Apr 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top